Perspective Therapeutics to Participate at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit & JonesResearch Virtual Radiopharma Day

Rhea-AI Summary

Perspective Therapeutics (NYSE AMERICAN: CATX), a radiopharmaceutical company, announced its participation in two upcoming events: the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit on October 8, 2024, in New York, NY, and the JonesResearch Virtual Radiopharma Day on October 29, 2024.

At the Oppenheimer Summit, Perspective's senior management will participate in two panel discussions: 'The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes' from 9:30 a.m. to 10:30 a.m. ET, and 'Supply Chain Challenges and Controversies: Ac225 Availability, Pb212 Logistics, The Last Mile' from 10:50 a.m. to 11:35 a.m. ET. They will also give a company presentation at 1:30 p.m. ET.

The JonesResearch event will feature a panel format. Webcasts for both events will be accessible live and archived for 90 days on the Perspective website's Investors page.

SEATTLE, Oct. 07, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or the “Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that its senior management will participate in panel discussions and company presentations at the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit in New York, NY on October 8, 2024 and the JonesResearch Virtual Radiopharma Day on October 29, 2024.

Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit

The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes
Format: Panel
Time: 9:30 a.m. – 10:30 a.m. ET

Supply Chain Challenges and Controversies: Ac225 Availability, Pb212 Logistics, The Last Mile
Format: Panel
Time: 10:50 a.m. – 11:35 a.m. ET

Company Presentations
Format: Presentation
Time: 1:30 p.m. ET

JonesResearch Virtual Radiopharma Day

Format: Panel

Webcast events can be accessed live, and replays will be archived for 90 days and available through the Investors page on the Perspective website. 

About Perspective Therapeutics, Inc.
Perspective Therapeutics, Inc., is a radiopharmaceutical development company that is pioneering advanced treatment applications for cancers throughout the body. The Company has proprietary technology that utilizes the alpha emitting isotope ²¹²Pb to deliver powerful radiation specifically to cancer cells via specialized targeting peptides. The Company is also developing complementary imaging diagnostics that incorporate the same targeting peptides which provide the opportunity to personalize treatment and optimize patient outcomes. This "theranostic" approach enables the ability to see the specific tumor and then treat it to potentially improve efficacy and minimize toxicity.

The Company's melanoma (VMT01) and neuroendocrine tumor (VMT-α-NET) programs have entered Phase 1/2a imaging and therapy trials for the treatment of metastatic melanoma and neuroendocrine tumors at several leading academic institutions. The Company has also developed a proprietary ²¹²Pb generator to secure key isotopes for clinical trial and commercial operations.

For more information, please visit the Company's website at www.perspectivetherapeutics.com.

Safe Harbor Statement
This press release contains forward-looking statements within the meaning of the United States Private Securities Litigation Reform Act of 1995. Statements in this press release that are not statements of historical fact are forward-looking statements. Words such as "may," "will," "should," "expect," "plan," "anticipate," "could," "intend," "target," "project," "estimate," "believe," "predict," "potential" or "continue" or the negative of these terms or other similar expressions are intended to identify forward-looking statements, though not all forward-looking statements contain these identifying words. Forward-looking statements in this press release include statements concerning, among other things, the Company's ability to pioneer advanced treatment applications for cancers throughout the body; the Company's prediction that complementary imaging diagnostics that incorporate certain targeting peptides provide the opportunity to personalize treatment and optimize patient outcomes; the Company's expectation that its "theranostic" approach enables the ability to see specific tumors and then treat it to potentially improve efficacy and minimize toxicity; the Company's ability to develop a proprietary 212Pb generator to secure key isotopes for clinical trial and commercial operations; the Company's clinical development plans and the expected timing thereof; the expected timing for availability and release of data; expectations regarding the potential market opportunities for the Company's product candidates; the potential functionality, capabilities, and benefits of the Company's product candidates and the potential application of these product candidates for other disease indications; the Company's expectations, beliefs, intentions, and strategies regarding the future; the Company's intentions to improve important aspects of care in cancer treatment; and other statements that are not historical fact.

The Company may not actually achieve the plans, intentions or expectations disclosed in the forward-looking statements, and you should not place undue reliance on the forward-looking statements. These forward-looking statements involve risks and uncertainties that could cause the Company's actual results to differ materially from the results described in or implied by the forward-looking statements. Certain factors that may cause the Company's actual results to differ materially from those expressed or implied in the forward-looking statements in this press release are described under the heading "Risk Factors" in the Company's most recent Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC"), in the Company's other filings with the SEC, and in the Company's future reports to be filed with the SEC and available at www.sec.gov. Forward-looking statements contained in this news release are made as of this date. Unless required to do so by law, we undertake no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

FAQ

What events will Perspective Therapeutics (CATX) participate in during October 2024?

Perspective Therapeutics (CATX) will participate in the Oppenheimer Targeted Radiopharmaceutical Therapies in Oncology Summit on October 8, 2024, and the JonesResearch Virtual Radiopharma Day on October 29, 2024.

What panels will Perspective Therapeutics (CATX) be involved in at the Oppenheimer Summit?

At the Oppenheimer Summit, Perspective Therapeutics (CATX) will participate in two panels: 'The Next Wave of TRTs – Targets, Targeting Technologies and Isotopes' and 'Supply Chain Challenges and Controversies: Ac225 Availability, Pb212 Logistics, The Last Mile'.

When is Perspective Therapeutics (CATX) scheduled to give their company presentation at the Oppenheimer Summit?

Perspective Therapeutics (CATX) is scheduled to give their company presentation at the Oppenheimer Summit on October 8, 2024, at 1:30 p.m. ET.

How long will the webcasts for Perspective Therapeutics (CATX) events be available for viewing?

The webcasts for Perspective Therapeutics (CATX) events will be archived and available for viewing for 90 days through the Investors page on the company's website.